a PDE5 inhibitor, is currently being evaluated in the POLARIS-AD Phase III trial (NCT05531526). The randomised trial compares AriBio’s drug against placebo to slow the progression of Alzheimer ...

The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...

A new study reports that mirodenafil, a newly developed oral phosphodiesterase type 5 (PDE5) inhibitor, is an efficacious and safe treatment for erectile dysfunction (ED). Many men with ED ...

The use of isoenzyme-selective phosphodiesterase (PDE) inhibitors is considered a great opportunity to treat various diseases of the human urogenital tract. PDE inhibitors, in particular the PDE5 ...